International Medical Journal (ISSN:13412051)

Aim and Scope

Aim-

International Medical Journal ISSN: (13412051) is an international open-access journal publishes twelve times each year. The "International Medical Journal" is a peer-reviewed, monthly, online international research journal, which publishes original articles, research articles, review articles with top-level work from all areas of Medical Science Research and their application including Aetiology, bioengineering, biomedicine, cardiology, chiropody, ENT etc. Researchers in all Medical Science and Pharmacy fields are encouraged to contribute articles based on recent research. Journal publishes research articles and reviews within the whole field of Medical Science and Pharmacy Research, and it will continue to provide information on the latest trends and developments in this ever-expanding subject. International Medical Journal journal covers almost all disciplines of Medical Science and Pharmacy. Researchers and students of M.B.B.S, M.D., D.T.C.D., GYNE., M.S., M.Pharma, And PhD are requested to send their original research articles to International Medical Journal.

Scope-

International Medical Journal ISSN: (13412051) is a peer-reviewed journal. The journal seeks to publish original research articles that are hypothetical and theoretical in its nature and that provide exploratory insights in the following fields but not limited to:

Anatomy Physiology Biochemistry Pharmacology
Pathology Forensic medicine Microbiology Community Medicine
Otorhinolaryngology Internal Medicine General Surgery Obstetrics and Gynecology
Radiology Pulmonary Medicine Dermatology and Venereal diseases Infectious Diseases AMA, Agricultural Mechanization in Asia, Africa and Latin America Teikyo Medical Journal Journal of the Mine Ventilation Society of South Africa Dokkyo Journal of Medical Sciences
Anaesthesia Cancer research Neurosurgery Orthopedics

See More Scopes

Latest Journals
International Medical Journal
Journal ID : IMJ-08-09-2020-604
Total View : 349

Abstract : Chemotherapy-induced peripheral neuropathy (CIPN) is one of the side effects related to chemotherapy treatment. The incidence ranges between 30 and 70 %. The current study was conducted to identify the use and effectiveness of coping strategies and their association with QOL among patients with CIPN. A cross-sectional correlational design using a convenience sampling approach was used in the current study. A sample of 100 participants was used to produce the study’s surveys including demographical and clinical information, an Arabic version of the quality of life questionnaire - chemotherapy-induced peripheral neuropathy (QLQ-CIPN20) and Arabic version of Jalowiec Coping Scale (JCS). Findings showed that confrontive coping strategies were the most commonly used by the participants (Mean =24.45, SD = 2.10) and also the effective (Mean 24.62, SD = 1.69). Strong negative relationships were found between use of coping strategies and QLQ-CIPN20 (r = -0.76, p<0.001) and strong negative relationships were found between effectiveness of coping strategies and QLQ-CIPN20 (r = -0.73, p<0.001). Since there is no reliable treatment for CIPN, therapeutic interventions that reduce the impact of CIPN through increasing the use of coping strategies is highly recommended in the treatment plan.
Full article
International Medical Journal
Journal ID : IMJ-07-09-2020-601
Total View : 351

Abstract : Dyspepsia or functional dyspepsia (FD) is a term often used to describe the abdominal discomfort and commonly used by many clinicians to account the various symptoms frequently observed in majority of patient of gastrointestinal disorder. FD possesses the group of common symptoms which draw the difference other than peptic ulcer disease and may lead to development of metabolic diseases if not treated within a framework. This review article emphasized on the functional dyspepsia and potential features of unique formulation i.e Unienzyme with MPS in the management of unenviable sign and symptoms of functional dyspepsia or non-ulcer dyspepsia.
Full article
International Medical Journal
Journal ID : IMJ-03-09-2020-598
Total View : 348

Abstract : Bay or laurel is a natural plant and its leaves are one of the fundamental regularly used cooking spices. The dry bay leaves are used to treat numerous digestive issues with nonvascular and antibacterial marketers. As a result, this examine turned into aimed to assess biological hobby of Jordanian bay leaves for its microbiological hobby in-vitro by way of extraction crucial oils from sparkling and dry leaves. The dried bay leaves have been extracted via hydro- distillation the use of methanol by means of a soxhlet extractor. The extracts had been focused and evaluated for mic assessments against bacillus coagulant, lactobacillus, streptococcus and candida albicans. In addition, bay leaves extracts have been evaluated for antioxidant activity the usage of dpph assay. The minimum inhibitory awareness (mic) confirmed that methanolic- extract of bay leaves has giant effects against bacillus coagulant and lactobacillus, where detectable effects towards other tested microorganism. But, all of bay leaves extracts displayed no consequences on candida albicans, however the methanolic extract displayed the most prominent stage. The oils confirmed true antibacterial interest towards each gram negative and gramtremendous microorganism. The capacity antioxidant pastime of the bay leaves and methanolic extract of seed oil from l. Nobili’s were evaluated to 94. 65(μg/ml) of DPPH ic 50.
Full article
International Medical Journal
Journal ID : IMJ-31-08-2020-595
Total View : 439

Abstract : Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor and is used in the standard adjuvant chemotherapy regimens to treat metastatic colorectal cancer (CRC). It is the commonest antiangiogenesis agent to treat metastatic CRC. Venous thromboembolism, delayed wound healing, and spontaneous bowel perforation are the adverse events following bevacizumab treatment. According to the timing of Histula growth relative to operation and starting bevacizumab treatment, Histulas are possibly secondary to bevacizumab treatment rather than postoperative complications. We reported, a single uncommon case of bevacizumab related enterocutaneous Histula on 60 years old woman patient whose already been done R0 resection for left side colon cancer 2 years before. Adjuvant chemotherapy already been given 3 weeks after surgery (using FOLFOX 6 regiments). After 1 year follow up, multiple nodul liver metastase were found on Abdominal CT Scan, the treatment was continued with Hirst line anti-angiogenesis regiment (FOLFOX + Bevacizumab) for another 6 months. On the last cycle, low output enterocutaneous Histula was found from the laparotomy scar, the chemotherapy was interrupted for the last cycle. Conservative treatment was done, parenteral nutritions were started and spontaneous Histula healing could achieved after 10 days and no need for surgical intervention. A small, but significant percentage of CRC cases develop Bevacizumab-associated Histulas, which should be detected early and is managed conservatively.
Full article
International Medical Journal
Journal ID : IMJ-26-08-2020-591
Total View : 548

Abstract : During the search for treatments for COVID-19, clinical trials for testing hydroxychloroquine were interrupted by the WHO already on May 25, 2020 after publication of a paper in the magazine The Lancet [2] that stated that patients who had received hydroxychloroquine presented mortality rates of 35% due to severe cardiac arrhythmias. This paper was withdrawn thirteen days after its publication because it was questioned by 120 scientists of various nationalities [3], both as regards the data collected and as regards the method, and on June 2, 2020 also eighty Italian medical doctors sent a letter to The Lancet and to the WHO in which they criticized the scientific contents of the paper. [4] Then, on June 3, 2020, Dr. Tedros Adhanom Ghebreyesus, Director-General of the WHO, allowed restart of recruitment of patients in tests regarding hydroxychloroquine in the Solidarity trial. [5] The Recovery trial then became the principal study on which the WHO based its final decision to confirm for all drug agencies suspension of use of hydroxychloroquine for the treatment of COVID-19.
Full article

Our Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates